WuXi Biologics (Cayman) Inc. (WXXWY) Stock Price & Analysis
WuXi Biologics (Cayman) Inc. (WXXWY) — price $11.17 (-1.24%), as of the Nov 19, 2026 trading session; market cap $23.0B.
Educational signal · not a buy or sell recommendation · How to read this
WuXi Biologics (Cayman) Inc. · WXXWY · Healthcare · Biotechnology
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $11.17 | |
| Change on the day | -1.24% | |
| 52-week range | $7.30–$14.80 | |
| Market capitalisation | $23.0B | — |
| Price / earnings (trailing) | 30.95 | |
| Shares traded on the day | 2.8K | |
| Beta (volatility vs the S&P 500) | 0.6 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for WuXi Biologics (Cayman) (WXXWY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 12, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is WuXi Biologics (Cayman) (WXXWY), and what does it report?
Short answer
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. WuXi Biologics (Cayman) Inc. (WXXWY) is classified as Healthcare / Biotechnology. Headquarters: No. 108, Meiliang Road, Wuxi, JS, 214092, CN. It employs 13,252 people and is led by Zhisheng Chen. In Q2 FY2026 it reported revenue of CN¥11.66B and net income of CN¥2.41B. The market values it at $23.0B.
What do the latest results show for WuXi Biologics (Cayman) (WXXWY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥11.66B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥11.66B | CN¥2.41B | CN¥1.16 (diluted) |
| Q4 FY2025 | CN¥11.62B | CN¥2.52B | CN¥1.18 (diluted) |
| Q2 FY2025 | CN¥9.95B | CN¥2.34B | CN¥1.10 (diluted) |
| Q4 FY2024 | CN¥10.10B | CN¥1.86B | CN¥0.86 (diluted) |
What are the financial strengths and risks for WuXi Biologics (Cayman) (WXXWY)?
Short answer · as of
The distress and quality screens read Altman Z 9.96 · Piotroski F 8. Trailing ratios: ROE 10.5% · ROA 7.7% · current ratio 3.04 · earnings yield 3.1% · free-cash-flow yield 2.8%.
How is WuXi Biologics (Cayman) scored?
Research dated 2026-09-12.
WuXi Biologics differs from a drug developer centered on its own pipeline and from a pure-play contract manufacturer confined to production. Its offering reaches from discovery and technical advice through testing, clinical support, commercial manufacturing, vaccine contract services and materials supply across major biopharmaceutical regions.
That breadth lets client work appear at different stages of a molecule’s lifecycle and gives WuXi opportunities to remain involved as programs progress. The dedicated WuXi Vaccines leadership structure also shows that vaccines sit within a broader biologics service organization rather than defining the whole company.
| Company | Price | Market value | Score |
|---|---|---|---|
| $67.79 Nov 18, 2026 | $7.42B | — 5-pillar · not comparable | |
| $2.01 Nov 19, 2026 | $135M | — 5-pillar · not comparable | |
| $2.34 Sep 15, 2026 | $1.14B | — Model unavailable | |
| $117.80 Nov 18, 2026 | $24.0B | — 5-pillar · not comparable | |
| $577.34 Nov 18, 2026 | $24.6B | — 5-pillar · not comparable | |
| $149.40 Nov 18, 2026 | $20.0B | — 5-pillar · not comparable | |
| $50.97 Nov 18, 2026 | $31.4B | — 5-pillar · not comparable | |
| $255.96 Nov 19, 2026 | $16.8B | — 5-pillar · not comparable | |
| $162.86 Nov 18, 2026 | $16.5B | — 5-pillar · not comparable | |
| $65.83 Nov 19, 2026 | $16.1B | — 5-pillar · not comparable | |
| $68.67 Nov 18, 2026 | $39.5B | — 5-pillar · not comparable | |
| $72.70 Nov 19, 2026 | $11.4B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held WXXWY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported WXXWY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about WuXi Biologics (Cayman) (WXXWY)?
- Is Fresenius SE KGaA (XTRA:FRE) Fairly Valued As Earnings And Its WuXi Deal Lift Interest?
- WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence
- Missed WuXi Biologics' Run? Here's The Bet Holders Made
- Fresenius and WuXi Bio team up in 37-strong biosimilar development deal
What Investors Ask About WuXi Biologics (Cayman) (WXXWY) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Is WuXi Biologics a drug owner or an outsourced development partner?
WuXi Biologics is primarily an outsourced partner serving drug-company clients from discovery through large-scale manufacturing. Its revenue therefore tracks client development and production work rather than dependence on sales from an internally owned medicine portfolio.
How does WuXi Vaccines fit within WuXi Biologics?
WuXi Vaccines extends the group’s contract development and manufacturing model into vaccines. Dedicated leadership for that operation sits alongside the wider biologics research, development and manufacturing platform.
What is the WXXWY stock price today?
The last price recorded for WuXi Biologics (Cayman) Inc. (WXXWY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com